Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

New Data, New Opportunities, and New Clinical Challenges Using Immunotherapies for TNBC
  • CME
  • MOC

Credits Available
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s)
Released: January 22, 2021 Expiration: January 21, 2022
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.
Heather McArthur, MD, MPH
Program Director
Kevin Kalinsky, MD, MS
Rita Nanda, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate available data on the use of ICI-based combinations as part of neoadjuvant/adjuvant therapy for early-stage triple-negative breast cancer
  • Plan first-line treatment with ICI-based therapy for individual patients with locally advanced or metastatic triple-negative breast cancer
  • Apply clinical evidence and expert recommendations on immune-targeted therapies with progressive triple-negative breast cancer after 1 or more previous lines of therapy
  • Manage specific treatment-related complications associated with the use of immune checkpoint inhibitors in patients with breast cancer
  • Recommend ongoing clinical trials assessing new therapeutic approaches for appropriate patients with triple-negative breast cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Heather McArthur, MD, MPH

Associate Professor
Department of Medicine
Medical Director, Breast Oncology
Samuel Oschin Comprehensive Cancer Center
Cedars-Sinai Medical Center
Los Angeles, California

Heather McArthur, MD, MPH, has disclosed that she has received funds for research support from Bristol-Myers Squibb and Merck and consulting fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Genomic Health, Merck, Pfizer, and Puma.

Faculty

Kevin Kalinsky, MD, MS

Director, Glen Family Breast Center
Hematology and Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS, has disclosed that his spouse/partner has ownership interest in and has received salary from Grail and that he has received consulting fees from Amgen, AstraZeneca, Eisai, Lilly, Merck, Novartis, Pfizer, and Seattle Genetics and funds for research support paid to his institution from Acetylon, Amgen, Calithera, CytomX, Genentech/Roche, Immunomedics, Incyte, Lilly, Novartis, Pfizer, Seattle Genetics, and Zentalis.
Rita Nanda, MD

Associate Professor of Medicine
Director, 
Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Rita Nanda, MD, has disclosed that she has received consulting fees from Aduro, Athenex, Clovis, Daiichi Sankyo, Genentech, Immunomedics, MacroGenics, Merck, Pfizer, and Seattle Genetics; funds for research support from AstraZeneca, Celgene, Corcept, Genentech/Roche, Immunomedics, Merck, OBI, Odonate, Pfizer, and Seattle Genetics; and other financial or material support from G1 Therapeutics.

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists and other healthcare providers who care for patients with triple-negative breast cancer.

Goal

The goal of this activity is to improve the competence and performance of learners to integrate immune checkpoint inhibitors into the treatment of triple-negative breast cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 22, 2021, through January 21, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Immune Checkpoint Inhibitor in Early-Stage TNBC (27 minutes)
  • CME
  • MOC

In this interactive recording of a live CCO Webinar, a dynamic expert panel discusses the latest data on optimal use of immune checkpoint inhibitors and antibody–drug conjugates for treating patients with early-stage through metastatic TNBC.
Heather McArthur, MD, MPH
Program Director
Kevin Kalinsky, MD, MS
Rita Nanda, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s)
Released: January 22, 2021 Expiration: January 21, 2022

This program is divided into several short segments which you can step through using the Video Chapters menu.

Related Content

Expert review and discussion of key data from SABCS 2020 in HER2-positive and hormone receptor–positive/HER2-negative disease, and metastatic triple-negative breast cancer from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: February 19, 2021 Expired: February 18, 2022

Download this short summary slideset oncurrent treatment for patients with HER2-positive breast cancer, from NCCN and Clinical Care Options (CCO).

Jame Abraham, MD, FACP Hope S. Rugo, MD Sara Tolaney, MD, MPH Released: February 9, 2021

Download these expert-selected slides on treating patients with HER2-positive metastatic breast cancer, from NCCN and Clinical Care Options (CCO).

Hope S. Rugo, MD Released: February 3, 2021

Download these expert-selected slides on treatment for patients with HER2-positive early breast cancer, from NCCN and Clinical Care Options (CCO).

Jame Abraham, MD, FACP Released: February 2, 2021

Video Chapters


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue